Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

The researchers found that the 15 candidate genes accounted for 0.40 percent of the variation in OUD risk, while age and sex accounted for 3.27 percent of the variation. Using the 15 variants as ...

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...

"However, while we know that genetic and ecological differences exist, few studies have looked at specific genes or the genome regions that may be affected. In our study, we present candidate ...

McGivney et al, A genome‐wide association study for recurrent laryngeal neuropathy in the Thoroughbred horse identifies a candidate gene that regulates myelin structure, Equine Veterinary ...